President Donald J. Trump announced the launch of a new website, “TrumpRx,” enabling Americans to purchase prescription medications directly from the government, bypassing insurance companies. The initiative aims to reduce drug costs by up to 85%, with Pfizer pledging to lower prices on select medications distributed in the U.S.
Trump stated that the program would “reduce drug prices by 100% in some cases” and projected annual savings of “hundreds of millions of dollars” for Americans. He highlighted Pfizer’s commitment to offering its prescription drugs to Medicaid at “most favored nation (MFN) prices,” a system that compares U.S. drug costs to those in other developed nations.
Under the agreement, Pfizer will provide discounted rates for medications such as Xeljanz (40% off for rheumatoid arthritis), Zavzpret (50% off for migraines), Eucrisa (80% off for dermatitis), and Duavee (85% off for female osteoporosis). The president emphasized the initiative’s goal to “end global freeloading on American pharmaceutical innovation,” criticizing the current system where other wealthy nations pay significantly less for drugs than U.S. patients.
The White House described the move as a breakthrough in lowering healthcare costs, stating it would benefit over 100 million Americans impacted by diseases treated by Pfizer’s medications. Trump framed the effort as fulfilling promises to prioritize patient affordability, contrasting it with what he called the political establishment’s failure to address rising drug prices.
